$2.06T
Total marketcap
$89.42B
Total volume
BTC 48.86%     ETH 17.27%
Dominance

Regeneron Pharmaceuticals REGN Stock

964.89 USD {{ price }} 1.264639% {{change_pct}}%
Exchange
NasdaqGS
Market Cap
105.91B USD
LOW - HIGH [24H]
947.85 - 973 USD
VOLUME [24H]
599.93K USD
{{ volume }}
P/E Ratio
27.39
Earnings per share
35.22 USD

Regeneron Pharmaceuticals Price Chart

Regeneron Pharmaceuticals REGN Financial and Trading Overview

Regeneron Pharmaceuticals stock price 964.89 USD
Previous Close 771.11 USD
Open 773.28 USD
Bid 0 USD x 1100
Ask 0 USD x 900
Day's Range 771.35 - 788.52 USD
52 Week Range 561.71 - 837.55 USD
Volume 646.9K USD
Avg. Volume 559.18K USD
Market Cap 85.91B USD
Beta (5Y Monthly) 0.231338
PE Ratio (TTM) 21.198431
EPS (TTM) 35.22 USD
Forward Dividend & Yield N/A (N/A)
Ex-Dividend Date N/A
1y Target Est 887.91 USD

REGN Valuation Measures

Enterprise Value 76.34B USD
Trailing P/E 21.198431
Forward P/E 18.051405
PEG Ratio (5 yr expected) 6.62
Price/Sales (ttm) 6.945134
Price/Book (mrq) 3.5695336
Enterprise Value/Revenue 6.171
Enterprise Value/EBITDA 15.036

Trading Information

Regeneron Pharmaceuticals Stock Price History

Beta (5Y Monthly) 0.231338
52-Week Change 34.79%
S&P500 52-Week Change 20.43%
52 Week High 837.55 USD
52 Week Low 561.71 USD
50-Day Moving Average 772.48 USD
200-Day Moving Average 744.78 USD

REGN Share Statistics

Avg. Volume (3 month) 559.18K USD
Avg. Daily Volume (10-Days) 486.87K USD
Shares Outstanding 107.89M
Float 102.52M
Short Ratio 2
% Held by Insiders 2.54%
% Held by Institutions 89.64%
Shares Short 1.14M
Short % of Float 1.23%
Short % of Shares Outstanding 1.04%

Dividends & Splits

Trailing Annual Dividend Rate 0
Trailing Annual Dividend Yield 0%
5 Year Average Dividend Yield N/A
Payout Ratio 0
Last Split Factor

Financial Highlights

Fiscal Year

Fiscal Year Ends December 31, 2022
Most Recent Quarter (mrq) March 31, 2023
Next Fiscal Year End December 31, 2023

Profitability

Profit Margin 33.81%
Operating Margin (ttm) 38.07%
Gross Margin 55.83%
EBITDA Margin 41.04%

Management Effectiveness

Return on Assets (ttm) 10.43%
Return on Equity (ttm) 19.27%

Income Statement

Revenue (ttm) 12.37B USD
Revenue Per Share (ttm) 115.42 USD
Quarterly Revenue Growth (yoy) 6.60%
Gross Profit (ttm) 7.02B USD
EBITDA 5.08B USD
Net Income Avi to Common (ttm) 4.18B USD
Diluted EPS (ttm) 36.94
Quarterly Earnings Growth (yoy) -16.00000000000000000000000000000000%

Balance Sheet

Total Cash (mrq) 8.96B USD
Total Cash Per Share (mrq) 83.65 USD
Total Debt (mrq) 2.7B USD
Total Debt/Equity (mrq) 11.5 USD
Current Ratio (mrq) 5.454
Book Value Per Share (mrq) 219.376

Cash Flow Statement

Operating Cash Flow (ttm) 4.28B USD
Levered Free Cash Flow (ttm) 1.71B USD

Profile of Regeneron Pharmaceuticals

Country United States
State NY
City Tarrytown
Address 777 Old Saw Mill River Road
ZIP 10591-6707
Phone 914 847 7000
Website https://www.regeneron.com
Industry Biotechnology
Sector(s) Healthcare
Full Time Employees 12099

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat neovascular age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Q&A For Regeneron Pharmaceuticals Stock

What is a current REGN stock price?

Regeneron Pharmaceuticals REGN stock price today per share is 964.89 USD.

How to purchase Regeneron Pharmaceuticals stock?

You can buy REGN shares on the NasdaqGS exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for Regeneron Pharmaceuticals?

The stock symbol or ticker of Regeneron Pharmaceuticals is REGN.

Which industry does the Regeneron Pharmaceuticals company belong to?

The Regeneron Pharmaceuticals industry is Biotechnology.

How many shares does Regeneron Pharmaceuticals have in circulation?

The max supply of Regeneron Pharmaceuticals shares is 109.76M.

What is Regeneron Pharmaceuticals Price to Earnings Ratio (PE Ratio)?

Regeneron Pharmaceuticals PE Ratio is 27.39608200 now.

What was Regeneron Pharmaceuticals earnings per share over the trailing 12 months (TTM)?

Regeneron Pharmaceuticals EPS is 35.22 USD over the trailing 12 months.

Which sector does the Regeneron Pharmaceuticals company belong to?

The Regeneron Pharmaceuticals sector is Healthcare.

Regeneron Pharmaceuticals REGN included in indexes

Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
{{ item.name }} {{ item.symbol }} {{ item.price }} {{ item.price_usd }}
{{ item.change_pct }}
{{ item.volume }} {{ item.volume_usd }} {{ item.low }} {{ item.low_usd }} {{ item.high }} {{ item.high_usd }} {{ item.components_count }} {{ item.volume }} {{ item.volume_usd }}
NASDAQ Composite IXIC 16041.62 USD
+2.96
5.07B USD 15869.24 USD 16061.82 USD 5.07B USD
S&P 500 INDEX SPX 5087.03 USD
+2.11
2.58B USD 2.58B USD
S&P 500 (Yahoo.com) GSPC 5087.03 USD
+2.11
2.58B USD 5038.83 USD 5094.39 USD 2.58B USD
US100 NDX 18004.7 USD
+3.01
1.04B USD 17808.3 USD 18034.8 USD 1.04B USD
Dow Jones U.S. Biotechnology In DJUSBT 2831.57 USD
+1.13
92.13M USD 2790.46 USD 2838.2 USD 92.13M USD
NASDAQ Global Select Market Com NQGS 7803.35 USD
+3.01
7717.83 USD 7813.27 USD
NASDAQ DM Ex Japan Large Mid Ca NQDMXJPLMAUD 2100.38 AUD 1410.69 USD
<0.01
2100.38 AUD 1410.69 USD 2100.38 AUD 1410.69 USD
NASDAQ-100 PM Settlement Value XQC 16331.98 USD
+1.13
16331.98 USD 16331.98 USD
The Capital Strength Index seek NQCAPST 3048.54 USD
+1.13
3021.22 USD 3051.82 USD
NASDAQ 100 Notional Net Total R XNDXNNR 20717.8 USD
+3.01
20491.8 USD 20752.4 USD
Nasdaq-100 ESG Net Notional Tot NDXESG24 1480.61 EUR 1620.46 USD
+3.39
1462.95 EUR 1601.13 USD 1481.28 EUR 1621.19 USD
Nasdaq-100 Micro Index XND 180.05 USD
+3.01
178.08 USD 180.35 USD
NASDAQ 100 Equal Weighted NDXE 7422.55 USD
+2.26
7360.82 USD 7438.19 USD
NASDAQ Composite Total Return I XCMP 19477.55 USD
+2.96
19268.25 USD 19502.07 USD
Stlmt ID NASDAQ Biotechnology NBX 4604.4 USD
-2.98
4555.41 USD 4917.8 USD